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Abstract
A special class of self-assembling peptides has been found to be capable of stabilizing the hydrophobic anticancer agent
ellipticine in aqueous solution. Here we study the effect of peptide sequence on the complex formation and its anticancer
activity in vitro. Three peptides, EAK16-II, EAK16-IV and EFK16-II, were selected to have either a different charge distribution
(EAK16-II vs. EAK16-IV) or a varying hydrophobicity (EAK16-II vs. EFK16-II). Results on their complexation with ellipticine
revealed that EAK16-II and EAK16-IV were able to stabilize protonated ellipticine or ellipticine microcrystals depending on
the peptide concentration; EFK16-II could stabilize neutral ellipticine molecules and ellipticine microcrystals. These different
molecular states of ellipticine were expected to affect ellipticine delivery. The anticancer activity of these complexes was
tested against two cancer cell lines: A549 and MCF-7, and related to the cell viability. The viability results showed that the
complexes with protonated ellipticine were effective in eradicating both cancer cells (viability ,0.05), but their dilutions in
water were not stable, leading to a fast decrease in their toxicity. In contrast, the complexes formulated with EFK16-II were
relatively stable upon dilution, but their original toxicity was relatively low compared to that with protonated ellipticine.
Overall, the charge distribution of the peptides seemed not to affect the complex formation and its therapeutic efficacy in
vitro; however, the increase in hydrophobicity of the peptides significantly altered the state of stabilized ellipticine and
increased the stability of the complexes. This work provides essential information for peptide sequence design in the
development of self-assembling peptide-based delivery of hydrophobic anticancer drugs.
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Introduction
Self-assembling peptides are emerging nano-biomaterials with
promising biomedical and bioengineering applications [1–3].
Among them is a special class of ionic-complementary peptides
discovered from a yeast Z-DNA binding protein [4]. These
peptides have a unique amphiphilic structure resulting from an
alternative arrangement of hydrophobic and hydrophilic amino
acids in sequence. They also consist of alternating positive and
negative charges at physiological conditions, resulting in ionic
complementarity. These peptides are capable of self-assembling
into very stable nanostructures or macroscopic membranes, which
can withstand high temperature, extreme pH, many digesting
enzymes and denaturation agents [4,5]. Moreover, they exhibit
good biocompatibility with many cultured mammalian cells [6]
and no detectable immune responses can be observed when being
introduced into animals [4,7,8]. These properties make them ideal
materials for tissue scaffolding [9–11], regenerative medicine
[7,8,12] and drug delivery [13–17].
The ionic-complementary self-assembling peptides have recent-
ly been used as novel nano-biomaterials in the local delivery of
hydrophilic peptide/protein drugs [16–19] and the formulation of
hydrophobic chemotherapeutics [20,21]. The biotinylated, self-
assembling peptide RADA16-II was found to be able to locally
deliver insulin-like growth factor 1 (IGF-1) to the myocardium,
and the peptide nanofibers provided sustained release of IGF-1 for
28 days [16]. These peptide nanofibers could also bind with a
human platelet derived growth factor (PDGF-BB) and deliver it in
vivo with sustained release to successfully decrease cardiomyocyte
death and preserve systolic function [17]. In addition to the
delivery of peptide/protein drugs, it has recently been demon-
strated that a self-assembling peptide, EAK16-II, can stabilize
hydrophobic compounds in aqueous solution and release them
into a cell membrane mimic in a control manner [14,20]. Further
studies revealed that such a peptide is capable of stabilizing the
hydrophobic anticancer agent ellipticine with different molecular
states in aqueous solution depending on the peptide and ellipticine
concentration, which in turn affects the ellipticine release from the
complexes [21]. These studies have shown great potential for the
use of the self-assembling peptides in drug delivery.
However, current studies of using self-assembling peptides for
drug delivery are still at their early stage. The development of a
self-assembling peptide-based delivery system requires better
design of peptide sequences for specific delivery goals. Previous
studies have shown that a difference in the charge distribution of
the self-assembling peptides significantly alters the nanostructure
of the peptide assemblies [22,23]. In addition, the charge
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pH [22]. The variations in peptide length, hydrophobicity and
ionic complementarity have been applied to control the formation
of self-assembling peptide matrices [24]. The resulting structure of
peptide assemblies will impact the construction of delivery vehicles
for different therapeutics. For example, delivery of protein or
siRNA drugs requires the cell penetration ability while cell
recognition is critical to achieve targeted delivery of anticancer
therapeutics [25–27]. Therefore, proper design of peptide
sequences becomes crucial to build functional peptide-based
carriers for effective drug delivery.
In this work, we carry out the study of peptide sequence effects
on the drug formulation and in vitro delivery. Three self-assembling
peptides, EAK16-II, EAK16-IV and EFK16-II, are chosen to
investigate the effects of charge distribution (type II vs. type IV)
and hydrophobicity (alanine A vs. phenylalanine F). A hydropho-
bic anticancer agent, ellipticine, is selected as a model drug,
following our early studies of this drug. The self-assembled
nanostructures of these peptides are first characterized by atomic
force microscopy (AFM); the hydrophobicity of the peptides
dissolved in aqueous solution is studied via surface tension
measurements, and fluorescence spectroscopy using a hydrophobic
fluorescent probe. These characteristics of the three peptides are
expected to impact their complexation with ellipticine, in terms of
ellipticine molecular states and the size of the resulting complexes.
The anticancer activity of the formulation is tested in vitro against
two cancer cell lines: non-small cell lung cancer cell A549 and
breast cancer cell MCF-7. The stability of the complexes after
serial dilutions in aqueous solution is further investigated. The
information obtained in this study is aimed at providing
appropriate design principles for selecting peptide sequences, to
construct advanced functional peptide carriers for anticancer drug
delivery.
Results and Discussion
The self-assembling peptide EAK16-II has been found to be
able to stabilize the hydrophobic anticancer agent ellipticine in
aqueous solution [20,21]; the ellipticine release kinetics from the
complexes into a cell membrane mimic has also been determined
[21]. Here, we report how the subtle differences in the peptide
sequence affect the properties of the peptide assemblies, the
formation of the peptide-ellipticine complexes, and the cellular
toxicity of the complexes.
Sequence effect on the peptide assemblies
Three self-assembling, ionic-complementary peptides, EAK16-
II, EAK16-IV and EFK16-II, are used in this study. The latter two
peptides are derived from the first one EAK16-II. All peptides
have 16 amino acids in sequence with 3 amino acid components:
E, K and A or F, as shown in Figure 1. EAK16-IV has a different
charge distribution of type IV (2222++++) from EAK16-II as
type II (22++22++), while the difference between EFK16-II
and EAK16-II is a more hydrophobic residue F replacing A in
EAK16-II. The slight differences in sequence among the three
peptides may significantly affect their assemblies and further
complexation with the hydrophobic molecules.
First, the peptide self-assembled nanostructures are found to be
different among the three peptides. The distribution of negative
and positive charges towards the two ends of an EAK16-IV
molecule at neutral pH is reported to cause the folding of the
peptide molecule to form a b-turn structure, resulting in the
formation of globular nanostructures [22,23]. EAK16-II, on the
other hand, has a preferable stretched molecular structure and
likely self-assembles into b-sheet rich nanofibers [23]. The
nanostructures of the two peptides are shown in Figure 2a and b
at a peptide concentration of 0.5 mg/mL. EAK16-II forms
straight nanofibers, connecting to networks (Figure 2a), whereas
EAK16-IV self-assembles into many more globular aggregates and
some short nanofibers (Figure 2b). The formation of short
nanofibers of EAK16-IV may be due to a relatively low pH
(,5) at such a high peptide concentration: when the pH is low
enough, some of the negatively charged residues can be
neutralized so that the intramolecular ionic interaction is
weakened. Thus, some peptides remain in a stretched form,
facilitating the formation of nanofibers [22].
The nanostructures of EFK16-II are also different from those of
EAK16-II as shown in Figure 2. EFK16-II forms predominant
nanofibers and these fibers tend to aggregate into fiber clusters.
This aggregation of nanofibers is probably due to a stronger
hydrophobic interaction between them. Such a stronger hydro-
phobic interaction is expected to come from the more hydropho-
bic phenylalanine (F) residues in the EFK16-II sequence,
compared with the alanine (A) residues in EAK16-II. This is
probably why the nanofibers of EFK16-II tend to form fiber
clusters, but those of EAK16-II are dispersed and form fiber
networks.
The hydrophobicity of the three peptides and their assemblies is
further characterized by surface activity and fluorescence
measurements, and the results are shown in Figure 3. Figure 3a
shows the surface tension as a function of time for the three
peptides at a peptide concentration of 0.5 mg/mL. For each
profile, the surface tension decreases fast initially and slowly
approaches equilibrium. This change with time corresponds to the
dynamic process of the adsorption of peptide molecules/
assemblies at the air-liquid interface, leading to the decrease in
surface tension [28]. Comparing the surface tensions of the three
profiles at 2 h (near equilibrium), they follow a trend: EAK16-
II.EAK16-IV.EFK16-II. In general, the lower the surface
tension is, the more hydrophobic the molecule is. Thus, the
hydrophobicity of the three peptides and their assemblies
(coexisting in solution) has a reversed trend: EFK16-II.EAK16-
IV.EAK16-II. This is reasonable that EFK16-II is the most
hydrophobic peptide among the three as it consists of phenylal-
anine residues, which is more hydrophobic than alanine residues
in EAK16-II and EAK16-IV. The reason why EAK16-IV has a
lower equilibrium surface tension than EAK16-II is probably due
to the formation of b-turn structure through intramolecular ionic
interaction in EAK16-IV. This conformational change may cause
the exposure of hydrophobic alanine residues toward the aqueous
phase, resulting in a slight increase in hydrophobicity of the
molecule and lowering the surface tension [22].
Figure 3b shows the fluorescence spectra of the ANS probe in
the three peptide solutions comparing to that in pure water (black
line and the inset). The normalized fluorescence intensities of ANS
in different solutions follow a trend: EFK16-II..EAK16-
II<EAK16-IV.H2O. Meanwhile, the peak positions of the
spectra are different; it locates at ,520 nm in pure water (inset),
but shifts to ,485 nm in EAK16-II and EAK16-IV solutions. The
ANS fluorescence spectrum has a peak of ,470 nm in the
EFK16-II solution. The changes in ANS fluorescence intensity
and peak position indicate that the ANS probe is in different
environments. ANS is a widely used probe to study protein
aggregation as well as cell membrane composition and function
due to its extreme sensitivity to the changes in the polarity of the
probed environment [29–31]. A less polar environment will cause
a shift of the fluorescence spectrum of ANS toward lower
wavelengths (blue shift) and a significant increase in the
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fluorescence in different peptide solutions (Figure 3b) can be
related to the hydrophobicity of the local environment where ANS
resides. This leads to a conclusion that EFK16-II provides a more
hydrophobic environment for ANS than the other two peptides.
These results also indicate that EFK16-II may have different
impacts on the complexation with the hydrophobic anticancer
agent ellipticine, compared with EAK16-II and EAK16-IV.
It is worth noting that the hydrophobicity determined by the
two methods may refer to two different situations. Surface tension
is a solution property and based on the molecular adsorption at the
interface, affecting the surface free energy. The adsorption process
involves three steps: i) diffusion of the molecules from the bulk to
the sub-interface; ii) transfer of the molecules from the sub-
interface to the interface; iii) rearrangement of the molecules at the
interface [32]. Considering diffusion to be the rate limiting step,
small molecules are expected to rapidly accumulate at the interface
due to their faster diffusion rate than large ones. Thus, in the self-
assembling peptide systems, the surface tension may reflect
predominantly the properties of peptide monomers and small
peptide assemblies, rather than those of the large peptide
aggregates. On the other hand, ANS fluorescence depends
pronouncedly on the local probe environment. The binding of
ANS to peptide monomers may not significantly affect its
fluorescence properties as it still ‘‘feels’’ surrounding solvent
molecules (i.e., water in this case). Only when the ANS probe is
enclosed in a different environment from the solvent does its
fluorescence greatly change. Therefore, the observed changes in
ANS fluorescence in Figure 3b should result from the properties of
peptide assemblies/aggregates. This is probably why the difference
between EAK16-II and EAK16-IV from surface tension is not
observed by the ANS fluorescence.
Figure 1. Molecular structures and sequences of EAK16-II, EAK16-IV and EFK16-II. N and C termini are protected by acetylation and
amidation, respectively.
doi:10.1371/journal.pone.0001956.g001
Figure 2. AFM images of the peptide nanostructures: (a) EAK16-II; (b) EAK16-IV; (c) EFK16-II. The peptide concentration is 0.5 mg/mL.
The scale bar is 200 nm.
doi:10.1371/journal.pone.0001956.g002
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It is found above that different peptide sequences affect the
peptide assemblies and their properties. Such effects further
influence the formation of peptide-ellipticine complexes. The
results are shown in Figure 4. The differences among the
complexes made of the three peptides can be directly visualized
from the appearance of the suspensions (Figure 4a). For EAK16-II,
the peptide-ellipticine solutions appear to be slightly turbid at
peptide concentrations of 0.2 and 0.04 mg/mL, indicating the
formation of large colloidal suspensions. However, at a concen-
tration of 0.5 mg/mL, the solution becomes clearer with a light
yellow color (far left vial). Similar appearances of the peptide-
ellipticine solutions are found for EAK16-IV (central three vials)
except that the solution looks less yellow at a peptide concentration
of 0.5 mg/mL. For EFK16-II, all solutions look cloudy.
Compared with the control sample (with the absence of peptides,
far right vial) that remains colorless and transparent, the changes
in the solution appearance of the peptide-ellipticine samples reveal
that ellipticine has been uptaken by the peptides and stabilized in
solution.
The different appearances of the solutions may indicate
different molecular states of ellipticine in the complexes. Recent
studies on the complexation of EAK16-II with ellipticine have
demonstrated that two molecular states of ellipticine, either
protonated or crystalline, can be obtained in the complexes
depending on the peptide and ellipticine concentrations [21]. The
protonation of ellipticine usually occurs at a higher peptide
concentration, related to a relatively low solution pH (,5, pKa of
ellipticine is ,6) [33]; protonated ellipticine can be stabilized by
ionic interaction with the negatively charged residues (glutamic
acid E in this case) of the peptide. The ellipticine microcrystals are
stabilized by peptide assemblies coating on the surface [20,21].
When ellipticine is protonated, it can dissolve in aqueous solution
and cause the solution to have a yellow, transparent appearance.
On the other hand, the suspended ellipticine microcrystals make
the solution turbid and cloudy. Thus, by looking at the appearance
of the samples, one can possibly predict that EAK16-II and
EAK16-IV can stabilize protonated or crystalline ellipticine while
ellipticine stabilized by EFK16-II may be predominantly in
microcrystal form.
The molecular state of ellipticine can be further elucidated by
the ellipticine fluorescence spectra. It has been found that
protonated ellipticine molecules have a fluorescence peak at
,520 nm while the fluorescence peak at ,430 nm is attributed to
neutral ellipticine molecules [34]; crystalline ellipticine exhibits a
fluorescence peak at ,470 nm with an extremely low intensity
[20]. The fluorescence spectra of the complexes with the three
peptides, EAK16-II, EAK16-IV and EFK16-II, are shown in
Figure 4b, c and d, respectively. For EAK16-II and EAK16-IV,
the complexes with 0.5 mg/mL peptide have a fluorescence peak
located ,520 nm, indicating that ellipticine is protonated. At
peptide concentrations below 0.5 mg/mL, the spectra have a peak
close to 470 nm with an extremely low intensity (insets in Figure 4b
and c), representing crystalline ellipticine. Interestingly, the
complexes with EFK16-II exhibit a fluorescence spectrum with a
major peak located at ,435 nm and a small shoulder covering the
wavelengths from 470 to 570 nm (Figure 4d), very different from
those of protonated and crystalline ellipticine. The peak located at
,435 nm represents neutral (non-charged) ellipticine, present as
individual molecules in a much less polar environment [34]. The
peak intensity is proportional to the EFK16-II concentration.
These results indicate that EFK16-II can stabilize neutral,
molecular ellipticine in aqueous solution; in contrast, the other
two molecular states of ellipticine, protonated and crystalline, can
be formed in the complexes with EAK16-II and EAK16-IV.
EFK16-II assemblies provide a more hydrophobic environment
than those of EAK16-II and EAK16-IV as shown in Figure 3b,
possibly facilitating the stabilization of neutral ellipticine mole-
cules. Note that in addition to neutral ellipticine, crystalline and
protonated ellipticine can coexist in the suspensions as indicated
by the turbid appearance of the suspensions and a shoulder from
the fluorescence spectra. The fluorescence signals from crystalline
ellipticine, however, are too small to be seen compared to those of
neutral ellipticine. The different quantum yields and overlapping
of the fluorescence signals from the three molecular states of
ellipticine make it difficult to determine the percentage of each
state among the three in the complexes. However, the total
amount of stabilized ellipticine can be obtained.
To determine how much ellipticine that can be stabilized in
solution by the peptides, aliquots of the peptide-ellipticine
suspensions were diluted into DMSO, and the UV absorption of
ellipticine was collected. The ellipticine absorbance was then
converted to corresponding ellipticine concentration in the
suspensions. This concentration was compared with the given
ellipticine concentration (0.04 mg/mL) to obtain the maximum
suspension (%) as shown in Figure 5. Initially in the preparation,
ellipticine is in solid form as a thin film at the bottom of the vial.
With the help of the peptides and mechanical stirring over time,
ellipticine can be uptaken and stabilized in the solution as
Figure 3. The hydrophobicity of the three peptides and their
assemblies by dynamic surface tension (a) and ANS fluores-
cence (b). The inset is the ANS fluorescence control with the absence
of peptides. The peptide concentration is 0.5 mg/mL, and the ANS
concentration is 10 mM.
doi:10.1371/journal.pone.0001956.g003
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ellipticine can be stabilized and suspended in solution; the
deposition of ellipticine thin film can still be observed at the
bottom of most sample vials. The amount of stabilized ellipticine
varies with the types of peptides and peptide concentrations. The
highest maximum suspension is found to be ,71% (by wt.) by
Figure 4. The formation of peptide-ellipticine complexes. (a) Photographs of the complexes with the three peptides at different peptide
concentrations and the ellipticine in pure water as a control. The normalized fluorescence spectra of ellipticine in the complexes with EAK16-II (b),
EAK16-IV (c) and EFK16-II (d). The insets show the spectra of the complexes with low peptide concentrations.
doi:10.1371/journal.pone.0001956.g004
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value decreases to ,56% for EAK16-IV and to ,46% for
EFK16-II. The lowest maximum suspension appears to be ,13%
by 0.04 mg/mL EAK16-IV, which is 3 folds higher than the
control (,4.5%) with the absence of peptides. The amount of
ellipticine suspended by the peptide in water is found to be much
higher than the reported solubility in water (,0.6 mM) [35]. With
the peptide concentration, the maximum suspension varies largely
for EAK16-II and EAK16-IV but not for EFK16-II. Overall,
EAK16-II appears to be the most effective peptide among the
three at stabilizing protonated ellipticine (at a high peptide
concentration of 0.5 mg/mL); EFK16-II, on the other hand, can
stabilize neutral ellipticine (in addition to crystalline and
protonated ellipticine), and it has less variation in the maximum
suspension with different peptide concentrations.
Size of the complexes
The size distribution of the peptide assemblies and complexes at
a peptide concentration of 0.5 mg/mL is shown in Figure 6. For
all three peptides, the peptide assemblies have a broad size
distribution from 10 to several hundred nanometers (Figure 6a).
They all have a major size population around 30 nm and a second
one corresponding to a shoulder located at ,300 nm, 100 nm and
200 nm for EAK16-II, EAK16-IV and EFK16-II, respectively.
The size distribution of EAK16-II obtained here correlates well
with our earlier findings, and the two populations represent short
peptide nanofibers and fiber clusters [36]. When the peptides
interact with ellipticine to form complexes, the size distributions
change significantly as shown in Figure 6b. Note that only the size
distributions of the complexes with EAK16-II and EAK16-IV are
shown in the plot because the size of the complexes with EFK16-II
is very polydispersed and over the detection limit of the
instrument. The EAK16-II-ellipticine complexes have a relatively
wider size distribution than EAK16-IV-ellipticine complexes; two
size populations with one around 90 nm and the other around
500 nm can be found in both distributions.
SEM imaging was applied as a complementary method to
examine the size and morphology of the complexes for the three
peptides at different peptide concentrations. The representative
images are shown in Figure 7. It is clearly seen that the dimensions
of the complexes with 0.5 mg/mL EAK16-II and EAK16-IV are
in the range of ,100–200 nm. For these two peptides, at peptide
concentrations below 0.5 mg/mL, the size of the complexes can
be as large as several micrometers. These complexes tend to have a
rod-like or fiber-like structure, aggregating into bundles or
entanglements. Such structures are very different from ellipticine
crystals suspended in water (control).
For EFK16-II, the dimensions of the complexes range from
hundreds of nanometers to several micrometers regardless of the
peptide concentrations. However, the morphology of these
complexes looks different according to the peptide concentration.
At 0.04 mg/mL, the majority of the complexes are also rod-like
although they seem to be shorter and more dispersed than those
with EAK16-II and EAK16-IV; at higher peptide concentrations,
the complexes appear to have irregular shapes. In addition, more
membrane-like structures are observed in the background with the
increase in EFK16-II concentration. These membrane-like
EFK16-II assemblies could play an important role in stabilizing
neutral ellipticine molecules. This may explain the increase in the
fluorescence intensity of neutral ellipticine as a function of EFK16-
II concentration shown in Figure 4d. Meanwhile, the ellipticine
microcrystals could be stabilized by the amphiphilic EFK16-II
monomers and small assemblies via forming peptide coatings on
the surface of the crystals, leading to the formation of cloudy
suspensions at all peptide concentrations.
Cellular toxicity of the complexes and their dilutions
From the characterization of the complexes above, it can be
summarized that peptide sequence will affect the molecular state of
ellipticine in the peptide-ellipticine complexes/assemblies.
EAK16-II and EAK16-IV can solubilize protonated ellipticine
or encapsulate ellipticine microcrystals, depending on the peptide
concentration. EFK16-II, on the other hand, can stabilize neutral
ellipticine molecules in addition to the other two states in aqueous
solution; the amount of neutral ellipticine that can be carried by
Figure 5. The maximum suspension (%) of ellipticine in
aqueous solution stabilized by the three peptides and with
the absence of peptides.
doi:10.1371/journal.pone.0001956.g005
Figure 6. The size distribution of the three peptides at 0.5 mg/
mL in pure water (a) and the complexes with 0.5 mg/mL
EAK16-II and EAK16-IV (b) by DLS. EPT: ellipticine.
doi:10.1371/journal.pone.0001956.g006
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and structure of the complexes also depend on the type of peptide
and peptide concentration. To gain more insight concerning these
differences in the molecular state of ellipticine as well as the size
and structure of the complexes, we investigated their cellular
toxicity against two cancer cell lines and the stability of the
complexes upon dilution in water. The information regarding the
complex stability after dilution would be useful for later animal
studies and preclinical experiments.
Figure 8 shows the viability of both A549 and MCF-7 cancer
cells upon being treated with peptide-ellipticine complexes for
48 h. For A549 cells (Figure 8a), all peptide-ellipticine complexes
reduce the cell viability to less than 0.3 compared with the viability
of non-treated cells (viability is 1). The toxicity of complexes is 2-
folds higher than that of the ellipticine control with the absence of
peptides (light green bar). The peptide controls have some toxicity
to the cells, causing the decrease of viability to the values between
0.6 and 0.8. The much lower cell viability resulted from the
peptide-ellipticine complexes compared with that from the
ellipticine control is probably due to the fact that the peptides
can stabilize large amounts of ellipticine in aqueous solution as
shown in Figure 5. Interestingly, the cells treated with the
Figure 7. SEM images of the complexes with the three peptides at different peptide concentrations and ellipticine crystals in pure
water as the control.
doi:10.1371/journal.pone.0001956.g007
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have almost zero viability. This may indicate that protonated
ellipticine is more effective at killing A549 cells than other forms of
ellipticine in the complexes. Such a result seems to contradict to
the already known fact that neutral ellipticine is the active form to
suppress the cancer cell growth [33].
The high efficacy of protonated ellipticine against cancer cells
may be explained in the following. First, the protonated ellipticine
has a positive charge, which can interact with a negatively charged
cell membrane surface, leading to accumulation of ellipticine at
the cell membrane surface. In addition, such a small molecule with
a hydrophobic characteristic is expected to cross the cell
membrane easily into the cytoplasm. Second, the protonated
ellipticine molecules release much faster from the complexes
compared with that from ellipticine microcrystals, due to the
differences in complex size and a relatively weak interaction
between protonated ellipticine and the peptide in the complexes
[21]. This accelerates the diffusion speed of ellipticine from the
complexes to the cells, facilitating a fast cellular uptake of
ellipticine. Third, although EFK16-II is capable of stabilizing
neutral ellipticine molecules, the amount of stabilized molecules
are probably low; the release rate can be slow due to a possibly
stronger hydrophobic interaction between neutral ellipticine and
EFK16-II in the complexes. This is probably why the complex
prepared with 0.5 mg/mL EFK16-II has much less effect on the
cellular toxicity than protonated ellipticine stabilized by EAK16-II
and EAK16-IV at the same peptide concentration.
For MCF-7 cells, the efficacy of protonated ellipticine on anti-
proliferation of the cells becomes more significant when compared
with the other forms of ellipticine (Figure 8b). The lowest cell
viability for the complexes with neutral ellipticine and/or
ellipticine crystals is around 0.5, which is about 70% of the
viability for the ellipticine control (,0.7). This percentage can be
as low as ,25% in the case of A549 cells. Such a difference may
imply that the peptide-ellipticine suspensions are less effective to
MCF-7 cells than to A549 cells. However, the complexes with
protonated ellipticine have similar efficacy at killing both cells,
although the reason behind is still unclear. It could be related to
the different sensitivity, internalization path way and/or cell
defense mechanism of the two cells in response to ellipticine.
Nevertheless, these results provide evidence that the molecular
state of ellipticine in the complexes significantly affects their
cellular toxicity. Accordingly, one should be aware that selection of
an appropriate formulation method is important in treating
different cancer cells.
Figure 9 shows the toxicity of the complexes with 0.5 mg/mL
EAK16-II, EAK16-IV and EFK16-II upon serial dilution in water
against both cell lines. The ellipticine control is diluted the same
way for comparison. It is clearly seen that dilution has significant
effect on the toxicity of the complexes with EAK16-II and
EAK16-IV, where ellipticine is stabilized in protonated form. For
A549 cells (Figure 9a), the cell viability is very low and less than
0.05 with these complexes before dilution; it increases largely to
above 0.6 for 16 times dilution of the complexes. A similar trend is
found for MCF-7 cells as the viability increases from less than 0.05
to above 0.7 (Figure 9b). Such changes imply that the complexes
may not be stable, altering the protonated form of ellipticine after
dilution in water. This instability of complexes is probably due to
the rising of solution pH, leading to the deprotonation of ellipticine
and the formation of ellipticine microcrystals after dilution. This
may explain why a sudden increase in cell viability occurs upon 2
times dilution for MCF-7 cells as they seem to be more sensitive to
protonated ellipticine than ellipticine microcrystals.
The EFK16-II-ellipticine complexes, on the other hand, exhibit
good stability upon dilution in water. The viability increases from
,0.25 to ,0.5 for A549 cells; for MCF-7 cells, it remains
unchanged at ,0.57 up to 4 times dilution and then slightly
increases to ,0.65 for 16 tines dilution. Such a good stability may
result from a stronger interaction between EFK16-II and
ellipticine in the complexes due to a higher hydrophobicity of
the peptide. In addition, a possible increase in solution pH after
dilution should not affect the state of the stabilized neutral
ellipticine molecules or ellipticine microcrystals. It is worth noting
that although these complexes are not as effective as protonated
ellipticine at killing cancer cells, their stability is much better,
which is especially important for practical applications in clinics
where drug dilution always occurs after administration into the
bloodstream.
Overall, this study has demonstrated the effect of peptide
sequence on its ability at stabilizing hydrophobic ellipticine in
protonated, neutral as well as crystalline forms in aqueous solution.
The difference in charge distribution (type II vs. type IV) on the
peptide sequence seems not to have much effect on the complex
formation and the molecular state of ellipticine in the complexes.
The size, anticancer activity and stability of the complexes are very
similar, although the charge distribution does affect, to some
degree, the peptide assemblies: nanofibers vs. globular aggregates.
It may be because the complexation of ellipticine with EAK16-II
and EAK16-IV is mainly based on the peptide monomers but not
on the peptide assembles. The increase in hydrophobicity of the
peptide by replacing alanine (A) with phenylalanine (F), however,
significantly alters the molecular state of ellipticine in the
complexes, the complex stability and its therapeutic effect due to
the following reasons: (i) the EFK16-II assemblies provide a more
Figure 8. Cellular toxicity of the peptides and their complexes
with ellipticine for A549 cells (a) and MCF-7 cells (b). The viability
of non-treated cells is 1 (M: cells were treated with culture medium). For
the solvent control, cells were treated with pure water (dark green bar);
for the drug control, cells were treated with ellipticine in pure water
with the absence of peptides (light green bar). Blue bars represent the
peptide controls where no ellipticine was added.
doi:10.1371/journal.pone.0001956.g008
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molecules can be solubilized; (ii) a stronger hydrophobic
interaction between ellipticine and EFK16-II may further enhance
the stability of the complexes upon dilution.
Different peptide sequences have different advantages in
formulating the ellipticine drug. For example, 0.5 mg/mL
EAK16-II (or EAK16-IV) can solubilize protonated ellipticine in
nanoscale complexes with high anticancer activity against both
A549 and MCF-7 cells, but these complexes are pH sensitive and
not very stable after dilution. In contrast, the complexes
formulated with 0.5 mg/mL EFK16-II are more stable upon
dilution, but most of their sizes are in the micrometer range and
their anticancer activity is relatively low. Nevertheless, these results
provide essential information to design an appropriate peptide
sequence that would optimize the delivery of hydrophobic
anticancer drugs. One could utilize the advantages of different
molecular states of ellipticine to improve the delivery efficacy,
through a proper peptide design to form a stable, peptide
nanocarriers, which can encapsulate neutral or crystalline
ellipticine; if such a carrier enters cells through endocytosis, the
encapsulated ellipticine becomes protonated at low pH in the
lysosomes, and the protonated ellipticine can be released and cross
the lysosome membrane into cytoplasm.
In conclusion, three ionic-complementary self-assembling
peptides, EAK16-II, EAK16-IV and EFK16-II, with different
charge distributions and hydrophobicities were found to be able
to stabilize the hydrophobic anticancer agent ellipticine in
aqueous solution. Ellipticine was stabilized in the form of
microcrystals, protonated and neutral molecules depending on
the peptide sequence and the peptide concentration. 0.5 mg/
mL EAK16-II and EAK16-IV stabilized protonated ellipticine
to form nano-complexes while crystalline ellipticine was
obtained in the complexes with these peptides at lower peptide
concentrations. On the other hand, EFK16-II was able to
stabilize both neutral and crystalline ellipticine within the range
of tested peptide concentrations; the amount of neutral
ellipticine that can be stabilized was proportional to the peptide
concentration. The different molecular states of stabilized
ellipticine in the complexes greatly affected the anticancer
activity of the complexes and their stability upon dilution in
water. The complexes with protonated ellipticine were found to
be very effective at killing both A549 and MCF-7 cells with a
Figure 9. Cellular toxicity of the complexes formulated with the three peptides at a peptide concentration of 0.5 mg/mL and their
serial dilutions in water for A549 cells (a) and MCF-7 cells (b). EPT: ellipticine.
doi:10.1371/journal.pone.0001956.g009
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very stable and their anticancer activity reduced significantly
after serial dilution in water. The complexes formulated with
EFK16-II (containing neutral ellipticine and ellipticine micro-
crystals), on the contrary, appeared to be stable after serial
dilution, although their original anticancer activity was rela-
tively low. These results showed that the differences in charge
distribution of the peptides did not have much effect on the
complex formation and their cellular toxicity, whereas the
increase in peptide hydrophobicity could strengthen the
interaction between the peptide and ellipticine, which gives
the stability of their complexes upon dilution. This study
provides necessary information on peptide sequence design to
construct functional peptide carriers for hydrophobic anticancer
drug delivery.
Materials and Methods
Materials
Three self-assembling, ionic-complementary peptides EAK16-II
(Mw=1657 g/mol, crude), EAK16-IV (Mw=1657 g/mol, crude)
and EFK16-II (Mw=2265 g/mol, crude) were obtained from
CanPeptide Inc. (Pointe-Claire, Quebec, Canada) and used
without further purification. The mass spectra and HPLC data
are presented in the Supporting Information (Figures S1, S2, S3,
S4, S5). Their sequences and molecular structures are shown in
Figure 1, where A corresponds to alanine, F to phenylalanine, E to
glutamic acid and K to lysine. The N-terminus and C-terminus of
the peptide were protected by acetyl and amino groups,
respectively. At pH,7, A and F are neutral, while E and K are
negatively and positively charged, respectively. The anticancer
agent ellipticine (99.8% pure) and 1-anilinonaphthalene-8-sulfonic
acid (ANS) were purchased from Sigma-Aldrich (Oakville, ON,
Canada) and used as received. Tetrahydrofuran (THF, reagent
grade 99%) and dimethyl sulfoxide (DMSO, spectral grade
.99%) were from Calendon Laboratories Ltd. (Georgetown,
ON, Canada) and Sigma-Aldrich (Oakville, ON, Canada),
respectively. Cell culture reagents including Dulbecco’s modified
eagle medium (DMEM), fetal bovine serum (FBS) and trypsin-
ETDA were purchased from Invitrogen Canada Inc. (Burlington,
ON, Canada). Phosphate buffer saline (PBS) and penicillin-
streptomycin (p/s, 10000 U) were obtained from MP Biomedicals
Inc. (Solon, OH, USA).
Sample preparation
Appropriate amounts of the peptide powder were first dissolved
in pure water (18 MV; Millipore Milli-Q system) to obtain fresh
peptide solutions at concentrations of 0.5, 0.2 and 0.04 mg/ml
(‘‘crude’’ peptide concentration). The solution was then sonicated
in a bath sonicator (Branson, model 2510) for 10 min. The peptide
solution at a concentration of 0.5 mg/mL was used to study the
differences among the three peptides in self-assembled nanos-
tructures, hydrophobicity and surface activity.
The peptide-ellipticine complexes were prepared by adding
1 mL of the fresh peptide solution into a glass vial containing a
thin film of 0.04 mg ellipticine at the bottom, followed by
mechanical stirring at 900 rpm for 24 h. 1 mL of pure water,
instead of peptide solution, was also added to another vial to make
a control sample. The purpose of using a relatively low ellipticine
concentration of 0.04 mg/mL in this study was to obtain
distinguishable cellular toxicity of the complexes and the control
sample. To make a thin film of ellipticine at the bottom of the
vials, 100 mL of 0.4 mg/mL ellipticine stock solution in THF was
transferred to the vials, and dried with gently blowing of filtered air
(0.22 mm pore size filter) for ,5 min. All the vials and solvents
were sterilized and the samples were prepared in a biological safety
cabinet to avoid possible contamination, for especially cell culture
experiments. For dynamic light scattering (DLS) measurements,
the solvents were filtered, and the samples were made in the
biosafety cabinet to eliminate potential dust contamination. The
complexes were photographed with a digital camera (Cannon
PowerShot A95) and characterized with several techniques to
obtain complex dimensions and molecular states of the ellipticine
in the complexes.
Determining the maximum suspension concentration of
ellipticine
The amount of suspended ellipticine in solution was determined
by the ellipticine UV-absorption. The peptide-ellipticine suspen-
sion was diluted 20 times in DMSO (resulting in a solvent mixture
of 95% DMSO and 5% water by volume) to dissolve ellipticine
from the complexes. 80 mL of the solution were then transferred to
a quartz microcell (70 mL) with a 1 cm light path and tested on a
UV-Vis spectrophotometer (Biochrom Ultraspec 4300 Pro, Cam-
bridge, England). The absorbance at 295 nm was converted to the
ellipticine concentration using Beer-Lambert’s law: absorbance
(Abs)=ecd, where e is the molar extinction coefficient, c is the
molar concentration of ellipticine, and d is the optical path length
(cm) [37]. The extinction coefficient was obtained as 5900061100
(R
2.0.995) from the linear fitting of ellipticine absorption as a
function of ellipticine concentration (2–20 mM) prepared in a
mixture of 95% DMSO and 5% water. The suspension
concentration of ellipticine was averaged from 3 measurements,
and compared with the given ellipticine concentration of 0.04 mg/
mL. Since not all ellipticine in the thin film at the bottom of the
vials could be stabilized and suspended in solution, the comparison
of the suspension concentration with the given ellipticine
concentration (0.04 mg/mL) would thus provide the maximum
percentage of the ellipticine suspension at each formulation
condition.
Atomic Force Microscopy (AFM)
The peptide self-assembled nanostructures were imaged on a
PicoScan
TM AFM (Molecular Imaging, Phoenix, AZ) in pure
water. The samples were prepared with the following procedure:
10 mL of 0.5 mg/mL peptide solution (,15 min after solution
preparation) were put on a freshly cleaved mica substrate, which
was fixed on an AFM sample plate; a custom made AFM liquid
cell was fastened on top of the mica substrate. The solution was
incubated for 10 s to allow the peptide assemblies to adhere to the
mica surface. The surface was then washed with pure water 15
times, and 500 mL of pure water were added into the cell prior to
AFM imaging. A scanner with a maximum scan area of 666 mm
2
was used to acquire the AFM images. It was operated with a
tapping mode using silicon nitride cantilevers with a nominal
spring constant of 0.58 N/m (DNP-S, Digital Instruments, Santa
Barbara, CA) and a typical tip radius of 10 nm. For the best
imaging quality, the tapping frequency was typically set between
16 kHz and 18 kHz and the scan rates controlled between 0.8 and
1 line/s. The experiments were conducted in an environmentally-
controlled chamber at room temperature to avoid evaporation of
the solution. All AFM images were obtained at a resolution of
2566256 pixels.
Surface tension measurements
The dynamic surface tension of fresh peptide solutions was
measured over a period of 2 h using the Axisymmtratic Drop
Sequence Effect of Peptides
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setup and operation of ADSA-P were described in an earlier
publication [38] and the references therein.
Fluorescence spectroscopy
The hydrophobicity of the three peptides and their assemblies
was investigated via ANS fluorescence [31,39]. 10 mM ANS
solution was prepared in a 10 mM phosphate buffer at pH 6. The
fresh peptide solutions were mixed with the same volume of the
ANS solution on a vortex mixer for 10 s. The ANS solution was
also mixed with the same volume of pure water as a control
sample. 60 mL of the mixed solution were transferred to a quartz
microcell and tested on a spectrafluorometer (Photon Technology
International, Type QM4-SE, London, Canada) with a continu-
ous xenon lamp as the light source. The sample was excited at
360 nm and the emission spectra were collected from 420 to
670 nm. The excitation and emission slit widths were set at
0.5 mm and 1.25 mm, respectively (0.5 and 1.25 mm corresponds
to 2 and 5 nm band path). The spectra were normalized with light
scattering of air at 360 nm, to correct the lamp fluctuations.
To study the molecular states of ellipticine in the complexes,
60 mL of the peptide-ellipticine suspensions were transferred to a
microcell and tested on the spectrafluorometer. The excitation was
set to be 294 nm and the emission was collected from 320 to
650 nm. The excitation and emission slit widths were set at
0.5 mm and 0.25 mm, respectively. The intensities were corrected
with an ellipticine standard (2 mM in ethanol, sealed and
degassed), to account for lamp fluctuations.
Dynamic Light Scattering (DLS)
The dimension of the peptide assemblies (0.5 mg/mL) and the
complexes from the peptide-ellipticine suspensions was investigated
onaZetasizerNanoZS(MalvernInstruments,Worcestershire,U.K.)
with appropriate viscosity and refractive index settings, and the
temperature was maintained at 25uC during the measurement. A
quartz microcell (45 mL) with a 3 mm light path was used. The
scattered light intensities of the samples at the angle of 173u were
collected. The intensity-based size distribution was obtained with the
multimodal algorithm CONTIN [40], provided in the software
package Dispersion Technology Software 5.0 (Malvern Instruments,
Worcestershire, U.K.). Three measurements were performed to
generate the intensity-based size distribution plot reported herein.
Scanning Electron Microscopy (SEM)
A LEO model 1530 field emission SEM (GmbH, Oberkochen,
Germany) was employed to study the morphology and dimensions
of the peptide-ellipticine complexes. The SEM sample was
prepared by depositing 10 mL of the peptide-ellipticine suspen-
sions on a freshly cleaved mica surface. The mica was affixed on
an SEM stub using a conductive carbon tape. The sample was
placed under a Petridish-cover for 10 min to allow the complexes
to adhere onto the mica surface. It was then washed once with a
total of 100 mL pure water and air-dried in a desicator overnight.
All samples were coated with a 20 nm thick gold layer prior to
SEM imaging; the images were acquired using the secondary
electron (SE2) mode at 5 kV.
In vitro cell viability studies
Two types of cancer cells, non-small cell lung cancer cell A549
and breast cancer cell MCF-7 (courtesy from Dr. Mingyao Liu at
the University of Toronto), were used for in vitro cellular toxicity
studies on the peptide-ellipticine complexes. The cells were
cultured in DMEM containing 10% FBS and 1% p/s at 37uC
and with 5% CO2. When cells grew to reach ,95% confluence,
they were detached from cell culture flasks with trypsin-EDTA and
resuspended in the cell culture media at concentrations of 5610
4
and 1610
5 cells/mL for A549 and MCF-7 cells, respectively. For
each type of cell, 200 mL of the cell suspensions were added into
each well of a clear, flat bottom 96-well plate (Costar) and
incubated overnight. 50 mL of the treatments (including the
complexes and control samples) were then added to the wells each
containing 150 mL of fresh culture media. The plates were
incubated for 48 h prior to perform the cell viability assay.
MTT assay was used to determine the cell viability after
different treatments. 5 mg of solid MTT was dissolved in 3 mL
PBS solution, followed by 10 times dilution in the culture
medium. All the treatments were taken out before 100 mLo ft h e
MTT solution was added to each well of the treated plates. The
plates were incubated for 4 h prior to the addition of 100 mLo f
the solubilization solution (anhydrous isopropanol with 0.1 N
HCl and 10% Triton X-100). After overnight incubation, the
absorbance at 570 nm was recorded on a microplate reader
(BMG FLUOstar OPTIMA) and subtracted by the background
signals at 690 nm. The absorption intensities were averaged from
4 replicates for each treatment and normalized to that obtained
from the untreated cells (negative control) to generate the cell
viability.
Supporting Information
Figure S1 Mass spectrum of EAK16-II.
Found at: doi:10.1371/journal.pone.0001956.s001 (0.50 MB TIF)
Figure S2 Mass spectrum of EAK16-IV.
Found at: doi:10.1371/journal.pone.0001956.s002 (0.09 MB TIF)
Figure S3 Mass spectrum of EFK16-II.
Found at: doi:10.1371/journal.pone.0001956.s003 (0.53 MB TIF)
Figure S4 HPLC data of EAK16-II. The purity of the peptide is
around 73%.
Found at: doi:10.1371/journal.pone.0001956.s004 (0.96 MB TIF)
Figure S5 HPLC data of EAK16-IV. The purity of the peptide
is around 83%.
Found at: doi:10.1371/journal.pone.0001956.s005 (0.24 MB TIF)
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